You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameArbekacin
Accession NumberDB06696
TypeSmall Molecule
GroupsApproved
DescriptionAn semisynthetic aminoglycoside antibiotic. Often used for treatment of multi-resistant bacterial infection such as methicillin-resistant Staphylococcus aureus (MRSA). Amikacin is also nephrotoxic and ototoxic.
Structure
Thumb
Synonyms
ABK
Arbekacina
Arbekacine
Arbekacinum
Habekacin
Haberacin
External Identifiers
  • 1665-RB
  • AHB-DBK
  • HABA-Dibekacin
  • HABA-DKB
  • HBK
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Arbekacin Sulfate
ThumbNot applicableDBSALT001108
Categories
UNIIG7V6SLI20L
CAS number51025-85-5
WeightAverage: 552.619
Monoisotopic: 552.311891658
Chemical FormulaC22H44N6O10
InChI KeyMKKYBZZTJQGVCD-XTCKQBCOSA-N
InChI
InChI=1S/C22H44N6O10/c23-4-3-12(30)20(34)28-11-5-10(26)18(37-21-9(25)2-1-8(6-24)35-21)17(33)19(11)38-22-16(32)14(27)15(31)13(7-29)36-22/h8-19,21-22,29-33H,1-7,23-27H2,(H,28,34)/t8-,9+,10-,11+,12-,13+,14-,15+,16+,17-,18+,19-,21+,22+/m0/s1
IUPAC Name
(2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-{[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4-{[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy}-3-hydroxycyclohexyl]-2-hydroxybutanamide
SMILES
NCC[[email protected]](O)C(=O)N[C@@H]1C[[email protected]](N)[C@@H](O[[email protected]]2O[[email protected]](CN)CC[[email protected]]2N)[[email protected]](O)[[email protected]]1O[[email protected]]1O[[email protected]](CO)[C@@H](O)[[email protected]](N)[[email protected]]1O
Pharmacology
IndicationArbekacin is used for the short term treatment of multi-resistant bacterial infections, such as methicillin-resistant Staphylococcus aureus (MRSA).
Structured Indications Not Available
PharmacodynamicsAminoglycosides, such as Arbekacin, work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA which consequently, leaves the bacterium unable to synthesize proteins vital to its growth. Energy is needed for aminoglycoside uptake into the bacterial cell. Anaerobes have less energy available for this uptake, so aminoglycosides are less active against anaerobes. Aminoglycosides are useful primarily in infections involving aerobic, gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter.
Mechanism of actionAminoglycosides, such as Arbekacin, inhibit protein synthesis in susceptible bacteria by irreversibly binding to bacterial 30S and 16S ribosomal subunits. Specifically Arbekacin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes.
TargetKindPharmacological actionActionsOrganismUniProt ID
30S ribosomal protein S12Proteinyes
inhibitor
Escherichia coli (strain K12)P0A7S3 details
Related Articles
AbsorptionAminoglycosides are not well absorbed from the gastrointestinal tract. Their absorption is markedly improved by parenteral administration.
Volume of distributionNot Available
Protein binding3-12%
MetabolismNot Available
Route of eliminationNot Available
Half life3 hours
ClearanceNot Available
ToxicityOtotoxicity and nephrotoxicity are the most serious adverse effects of aminoglycoside therapy and are more likely to occur in patients with a history of renal impairment or who are receiving other ototoxic and/or nephrotoxic drugs. Normal duration of IM or IV aminoglycoside therapy is 7-10 days. Although a longer duration may be necessary in some cases, toxicity is more likely to occur when aminoglycoside treatment is continued for longer than 10 days.
Affected organisms
  • Enteric bacteria and other eubacteria
  • Escherichia coli
  • Staphylococcus aureus
  • Acinetobacter
Pathways
PathwayCategorySMPDB ID
Arbekacin Action PathwayDrug actionSMP00713
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AceclofenacAceclofenac may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
AcetovanilloneAcetovanillone may decrease the excretion rate of Arbekacin which could result in a higher serum level.Investigational
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Arbekacin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Vet Approved
AdapaleneAdapalene may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
Alendronic acidArbekacin may increase the hypocalcemic activities of Alendronic acid.Approved
AmdinocillinThe serum concentration of Arbekacin can be decreased when it is combined with Amdinocillin.Withdrawn
AmoxicillinThe serum concentration of Arbekacin can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Arbekacin.Approved, Investigational
AmpicillinThe serum concentration of Arbekacin can be decreased when it is combined with Ampicillin.Approved, Vet Approved
AnisodamineAnisodamine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Investigational
AntipyrineAntipyrine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
AnvirzelThe serum concentration of Anvirzel can be decreased when it is combined with Arbekacin.Investigational
ApremilastApremilast may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
Atracurium besylateArbekacin may increase the respiratory depressant activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the excretion rate of Arbekacin which could result in a higher serum level.Withdrawn
AzelastineAzelastine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
AzidocillinThe serum concentration of Arbekacin can be decreased when it is combined with Azidocillin.Approved
AzlocillinThe serum concentration of Arbekacin can be decreased when it is combined with Azlocillin.Approved
BacampicillinThe serum concentration of Arbekacin can be decreased when it is combined with Bacampicillin.Approved
BalsalazideBalsalazide may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
BenoxaprofenBenoxaprofen may decrease the excretion rate of Arbekacin which could result in a higher serum level.Withdrawn
Benzathine benzylpenicillinThe serum concentration of Arbekacin can be decreased when it is combined with Benzathine benzylpenicillin.Approved, Vet Approved
BenzylpenicillinThe serum concentration of Arbekacin can be decreased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicillin PotassiumThe serum concentration of Arbekacin can be decreased when it is combined with Benzylpenicillin Potassium.Approved
Benzylpenicilloyl PolylysineThe serum concentration of Arbekacin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
Betulinic AcidBetulinic Acid may decrease the excretion rate of Arbekacin which could result in a higher serum level.Investigational
Botulinum Toxin Type AArbekacin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BArbekacin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BromfenacBromfenac may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
BucillamineBucillamine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Arbekacin.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Arbekacin.Approved
CarbenicillinThe serum concentration of Arbekacin can be decreased when it is combined with Carbenicillin.Approved
CarboplatinArbekacin may increase the ototoxic activities of Carboplatin.Approved
CarindacillinThe serum concentration of Arbekacin can be decreased when it is combined with Carindacillin.Approved
CarprofenCarprofen may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Experimental
CelecoxibCelecoxib may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ChloroquineChloroquine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Vet Approved
Cisatracurium besylateArbekacin may increase the respiratory depressant activities of Cisatracurium besylate.Approved
CisplatinCisplatin may increase the nephrotoxic activities of Arbekacin.Approved
ClodronateArbekacin may increase the hypocalcemic activities of Clodronate.Approved, Investigational, Vet Approved
ClonixinClonixin may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
CloxacillinThe serum concentration of Arbekacin can be decreased when it is combined with Cloxacillin.Approved, Vet Approved
ColistimethateArbekacin may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
CurcuminCurcumin may decrease the excretion rate of Arbekacin which could result in a higher serum level.Investigational
CyclacillinThe serum concentration of Arbekacin can be decreased when it is combined with Cyclacillin.Approved
CyclosporineArbekacin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneD-Limonene may decrease the excretion rate of Arbekacin which could result in a higher serum level.Investigational
DecamethoniumArbekacin may increase the respiratory depressant activities of Decamethonium.Approved
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Arbekacin.Approved
DiclofenacDiclofenac may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Vet Approved
DicloxacillinThe serum concentration of Arbekacin can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
DiflunisalDiflunisal may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Arbekacin.Approved
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Arbekacin.Approved
Domoic AcidArbekacin may increase the respiratory depressant activities of Domoic Acid.Experimental
Doxacurium chlorideArbekacin may increase the respiratory depressant activities of Doxacurium chloride.Approved
DroxicamDroxicam may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
DuvelisibDuvelisib may decrease the excretion rate of Arbekacin which could result in a higher serum level.Investigational
E6201E6201 may decrease the excretion rate of Arbekacin which could result in a higher serum level.Investigational
EbselenEbselen may decrease the excretion rate of Arbekacin which could result in a higher serum level.Investigational
EpirizoleEpirizole may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Arbekacin.Approved
EtanerceptEtanercept may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
Etidronic acidArbekacin may increase the hypocalcemic activities of Etidronic acid.Approved
EtodolacEtodolac may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
EtoricoxibEtoricoxib may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
exisulindexisulind may decrease the excretion rate of Arbekacin which could result in a higher serum level.Investigational
FenbufenFenbufen may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
FenoprofenFenoprofen may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
FloctafenineFloctafenine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Withdrawn
FlucloxacillinThe serum concentration of Arbekacin can be decreased when it is combined with Flucloxacillin.Approved
FlunixinFlunixin may decrease the excretion rate of Arbekacin which could result in a higher serum level.Vet Approved
FlurbiprofenFlurbiprofen may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
FoscarnetFoscarnet may increase the nephrotoxic activities of Arbekacin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Arbekacin.Approved, Vet Approved
Gallamine TriethiodideArbekacin may increase the respiratory depressant activities of Gallamine Triethiodide.Approved
HigenamineHigenamine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Investigational
HMPL-004HMPL-004 may decrease the excretion rate of Arbekacin which could result in a higher serum level.Investigational
IbandronateArbekacin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
IbuprofenIbuprofen may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
IbuproxamIbuproxam may decrease the excretion rate of Arbekacin which could result in a higher serum level.Withdrawn
IcatibantIcatibant may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
IndomethacinIndomethacin may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of Arbekacin which could result in a higher serum level.Withdrawn
IsoxicamIsoxicam may decrease the excretion rate of Arbekacin which could result in a higher serum level.Withdrawn
KebuzoneKebuzone may decrease the excretion rate of Arbekacin which could result in a higher serum level.Experimental
KetoprofenKetoprofen may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Vet Approved
KetorolacKetorolac may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
LeflunomideLeflunomide may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
LisofyllineLisofylline may decrease the excretion rate of Arbekacin which could result in a higher serum level.Investigational
LornoxicamLornoxicam may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
LoxoprofenLoxoprofen may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
LumiracoxibLumiracoxib may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
MannitolMannitol may increase the nephrotoxic activities of Arbekacin.Approved, Investigational
MasoprocolMasoprocol may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
MecamylamineArbekacin may increase the neuromuscular blocking activities of Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
MeloxicamMeloxicam may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Vet Approved
MesalazineMesalazine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
MetamizoleMetamizole may decrease the excretion rate of Arbekacin which could result in a higher serum level.Withdrawn
MeticillinThe serum concentration of Arbekacin can be decreased when it is combined with Meticillin.Approved
MetocurineArbekacin may increase the respiratory depressant activities of Metocurine.Approved
Metocurine IodideArbekacin may increase the respiratory depressant activities of Metocurine Iodide.Withdrawn
MezlocillinThe serum concentration of Arbekacin can be decreased when it is combined with Mezlocillin.Approved
MivacuriumArbekacin may increase the respiratory depressant activities of Mivacurium.Approved
MizoribineMizoribine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Investigational
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
NabumetoneNabumetone may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
NafamostatNafamostat may decrease the excretion rate of Arbekacin which could result in a higher serum level.Investigational
NafcillinThe serum concentration of Arbekacin can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
NaproxenNaproxen may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Vet Approved
NCX 4016NCX 4016 may decrease the excretion rate of Arbekacin which could result in a higher serum level.Investigational
NeosaxitoxinArbekacin may increase the respiratory depressant activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
Niflumic AcidNiflumic Acid may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
NimesulideNimesulide may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Withdrawn
NitroaspirinNitroaspirin may decrease the excretion rate of Arbekacin which could result in a higher serum level.Investigational
OlopatadineOlopatadine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
OlsalazineOlsalazine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
OrgoteinOrgotein may decrease the excretion rate of Arbekacin which could result in a higher serum level.Vet Approved
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Arbekacin.Approved
OxacillinThe serum concentration of Arbekacin can be decreased when it is combined with Oxacillin.Approved
OxaprozinOxaprozin may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Arbekacin which could result in a higher serum level.Withdrawn
PamidronateArbekacin may increase the hypocalcemic activities of Pamidronate.Approved
PancuroniumArbekacin may increase the respiratory depressant activities of Pancuronium.Approved
ParecoxibParecoxib may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
PhenoxymethylpenicillinThe serum concentration of Arbekacin can be decreased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenylbutazonePhenylbutazone may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Vet Approved
PimecrolimusPimecrolimus may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
PipecuroniumArbekacin may increase the respiratory depressant activities of Pipecuronium.Approved
PiperacillinThe serum concentration of Arbekacin can be decreased when it is combined with Piperacillin.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Arbekacin.Experimental
PirfenidonePirfenidone may decrease the excretion rate of Arbekacin which could result in a higher serum level.Investigational
PiroxicamPiroxicam may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
PivampicillinThe serum concentration of Arbekacin can be decreased when it is combined with Pivampicillin.Approved
PivmecillinamThe serum concentration of Arbekacin can be decreased when it is combined with Pivmecillinam.Approved
Procaine benzylpenicillinThe serum concentration of Arbekacin can be decreased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
PropacetamolPropacetamol may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
PTC299PTC299 may decrease the excretion rate of Arbekacin which could result in a higher serum level.Investigational
PyrantelArbekacin may increase the respiratory depressant activities of Pyrantel.Approved, Vet Approved
RapacuroniumArbekacin may increase the respiratory depressant activities of Rapacuronium.Withdrawn
ResveratrolResveratrol may decrease the excretion rate of Arbekacin which could result in a higher serum level.Experimental, Investigational
RisedronateArbekacin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
RocuroniumArbekacin may increase the respiratory depressant activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the excretion rate of Arbekacin which could result in a higher serum level.Investigational, Withdrawn
SalicylamideSalicylamide may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
Salicylic acidSalicylic acid may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Vet Approved
SalsalateSalsalate may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
SeratrodastSeratrodast may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
SRT501SRT501 may decrease the excretion rate of Arbekacin which could result in a higher serum level.Investigational
SuccinylcholineArbekacin may increase the respiratory depressant activities of Succinylcholine.Approved
SulbactamThe serum concentration of Arbekacin can be decreased when it is combined with Sulbactam.Approved
SulfasalazineSulfasalazine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
SulindacSulindac may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
SultamicillinThe serum concentration of Arbekacin can be decreased when it is combined with Sultamicillin.Investigational
SuprofenSuprofen may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Withdrawn
TazobactamThe serum concentration of Arbekacin can be decreased when it is combined with Tazobactam.Approved
Technetium tc 99m etidronateArbekacin may increase the hypocalcemic activities of Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateArbekacin may increase the hypocalcemic activities of Technetium Tc-99m Medronate.Approved
TenofovirThe serum concentration of Arbekacin can be increased when it is combined with Tenofovir.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
TepoxalinTepoxalin may decrease the excretion rate of Arbekacin which could result in a higher serum level.Vet Approved
TeriflunomideTeriflunomide may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
TicarcillinThe serum concentration of Arbekacin can be decreased when it is combined with Ticarcillin.Approved, Vet Approved
TiludronateArbekacin may increase the hypocalcemic activities of Tiludronate.Approved, Vet Approved
TinoridineTinoridine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Investigational
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
TolmetinTolmetin may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Arbekacin.Approved
TranilastTranilast may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
Trisalicylate-cholineTrisalicylate-choline may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
TubocurarineArbekacin may increase the respiratory depressant activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the excretion rate of Arbekacin which could result in a higher serum level.Investigational, Withdrawn
VancomycinVancomycin may increase the nephrotoxic activities of Arbekacin.Approved
VecuroniumArbekacin may increase the respiratory depressant activities of Vecuronium.Approved
ZaltoprofenZaltoprofen may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ZileutonZileuton may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational, Withdrawn
Zoledronic acidArbekacin may increase the hypocalcemic activities of Zoledronic acid.Approved
ZomepiracZomepirac may decrease the excretion rate of Arbekacin which could result in a higher serum level.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

Shinichi Kondo, Seiji Shibahara, Takayuki Usui, Toshiaki Kudo, Shuichi Gomi, Atsushi Tamura, Yoko Ikeda, Daishiro Ikeda, Tomio Takeuchi, “Dibekacin derivatives and arbekacin derivatives active against resistant bacteria, and the production thereof.” U.S. Patent US5618795, issued October, 1989.

US5618795
General References
  1. Inoue M, Nonoyama M, Okamoto R, Ida T: Antimicrobial activity of arbekacin, a new aminoglycoside antibiotic, against methicillin-resistant Staphylococcus aureus. Drugs Exp Clin Res. 1994;20(6):233-9. [PubMed:7758395 ]
  2. Morikawa K, Nonaka M, Yoshikawa Y, Torii I: Synergistic effect of fosfomycin and arbekacin on a methicillin-resistant Staphylococcus aureus-induced biofilm in a rat model. Int J Antimicrob Agents. 2005 Jan;25(1):44-50. [PubMed:15620825 ]
  3. Doi Y, Yokoyama K, Yamane K, Wachino J, Shibata N, Yagi T, Shibayama K, Kato H, Arakawa Y: Plasmid-mediated 16S rRNA methylase in Serratia marcescens conferring high-level resistance to aminoglycosides. Antimicrob Agents Chemother. 2004 Feb;48(2):491-6. [PubMed:14742200 ]
  4. Antimicrobial agents and Chemotherapy [Link]
External Links
ATC CodesJ01GB12
AHFS Codes
  • 08:12.02
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9365
Blood Brain Barrier-0.9659
Caco-2 permeable-0.7588
P-glycoprotein substrateSubstrate0.5786
P-glycoprotein inhibitor INon-inhibitor0.7254
P-glycoprotein inhibitor IINon-inhibitor0.8424
Renal organic cation transporterNon-inhibitor0.8676
CYP450 2C9 substrateNon-substrate0.8204
CYP450 2D6 substrateNon-substrate0.8289
CYP450 3A4 substrateNon-substrate0.559
CYP450 1A2 substrateNon-inhibitor0.933
CYP450 2C9 inhibitorNon-inhibitor0.9392
CYP450 2D6 inhibitorNon-inhibitor0.909
CYP450 2C19 inhibitorNon-inhibitor0.9122
CYP450 3A4 inhibitorNon-inhibitor0.9564
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9002
Ames testNon AMES toxic0.7048
CarcinogenicityNon-carcinogens0.9617
BiodegradationNot ready biodegradable0.6627
Rat acute toxicity1.8593 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9902
hERG inhibition (predictor II)Non-inhibitor0.5444
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point178Not Available
Predicted Properties
PropertyValueSource
Water Solubility41.0 mg/mLALOGPS
logP-2.9ALOGPS
logP-6.9ChemAxon
logS-1.1ALOGPS
pKa (Strongest Acidic)12.49ChemAxon
pKa (Strongest Basic)9.99ChemAxon
Physiological Charge5ChemAxon
Hydrogen Acceptor Count15ChemAxon
Hydrogen Donor Count11ChemAxon
Polar Surface Area297.27 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity129.08 m3·mol-1ChemAxon
Polarizability56.65 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as amino sugars. These are sugars having one alcoholic hydroxy group replaced by an amino group; systematically known as x-amino-x-deoxymonosaccharides. These compounds do not include Glycosylamines.
KingdomOrganic compounds
Super ClassOrganooxygen compounds
ClassCarbohydrates and carbohydrate conjugates
Sub ClassAminosaccharides
Direct ParentAmino sugars
Alternative Parents
Substituents
  • 4,6-disubstituted 2-deoxystreptamine
  • Aminoglycoside core
  • 2-deoxystreptamine aminoglycoside
  • Gamma amino acid or derivatives
  • Glucosamine
  • Amino sugar
  • O-glycosyl compound
  • Glycosyl compound
  • Cyclohexylamine
  • Cyclohexanol
  • Fatty acyl
  • Oxane
  • N-acyl-amine
  • Monosaccharide
  • Fatty amide
  • Cyclic alcohol
  • 1,3-aminoalcohol
  • Secondary carboxylic acid amide
  • Secondary alcohol
  • Carboxamide group
  • 1,2-aminoalcohol
  • Oxacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Acetal
  • Hydrocarbon derivative
  • Primary amine
  • Primary alcohol
  • Organonitrogen compound
  • Primary aliphatic amine
  • Carbonyl group
  • Amine
  • Alcohol
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
yes
Actions
inhibitor
General Function:
Trna binding
Specific Function:
With S4 and S5 plays an important role in translational accuracy.Interacts with and stabilizes bases of the 16S rRNA that are involved in tRNA selection in the A site and with the mRNA backbone. Located at the interface of the 30S and 50S subunits, it traverses the body of the 30S subunit contacting proteins on the other side and probably holding the rRNA structure together. The combined cluste...
Gene Name:
rpsL
Uniprot ID:
P0A7S3
Molecular Weight:
13736.995 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Funatsu G, Yaguchi M, Wittmann-Liebold B: Primary stucture of protein S12 from the small Escherichia coli ribosomal subunit. FEBS Lett. 1977 Jan 15;73(1):12-7. [PubMed:320034 ]
  4. Carter AP, Clemons WM, Brodersen DE, Morgan-Warren RJ, Wimberly BT, Ramakrishnan V: Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature. 2000 Sep 21;407(6802):340-8. [PubMed:11014183 ]
Comments
comments powered by Disqus
Drug created on May 05, 2010 10:31 / Updated on August 17, 2016 12:24